Inhibikase Therapeutics Inc. (IKT): Price and Financial Metrics
IKT Price/Volume Stats
| Current price | $1.96 | 52-week high | $4.20 |
| Prev. close | $1.96 | 52-week low | $1.12 |
| Day low | $1.91 | Volume | 185,178 |
| Day high | $2.01 | Avg. volume | 152,916 |
| 50-day MA | $2.03 | Dividend yield | N/A |
| 200-day MA | $2.21 | Market Cap | 145.71M |
IKT Stock Price Chart Interactive Chart >
Inhibikase Therapeutics Inc. (IKT) Company Bio
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. Its research phase products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
IKT Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IKT Price Returns
| 1-mo | 5.95% |
| 3-mo | 0.00% |
| 6-mo | -40.24% |
| 1-year | 18.07% |
| 3-year | -67.97% |
| 5-year | N/A |
| YTD | -39.69% |
| 2024 | 155.91% |
| 2023 | -57.67% |
| 2022 | -65.99% |
| 2021 | -78.70% |
| 2020 | N/A |